BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Esposito I, Marciano S, Trinks J. Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C. Expert Opin Drug Metab Toxicol 2018;14:649-57. [PMID: 29855221 DOI: 10.1080/17425255.2018.1483336] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Ye F, Huang J, Wang H, Luo C, Zhao K. Targeting epigenetic machinery: Emerging novel allosteric inhibitors. Pharmacol Ther 2019;204:107406. [PMID: 31521697 DOI: 10.1016/j.pharmthera.2019.107406] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
2 Abdallah IA, Hammad SF, Bedair A, Mansour FR. A green homogeneous liquid-liquid microextraction method for spectrophotometric determination of daclatasvir in human plasma. Sustainable Chemistry and Pharmacy 2021;22:100498. [DOI: 10.1016/j.scp.2021.100498] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]